Hims & Hers Health (HIMS) has disclosed plans to shut down Apostrophe, its acne treatment business. This change is part of ...

Hims & Hers Health will shut down Apostrophe, its personalized acne treatments dermatology business, the company said on Friday. Apostrophe is being shut down to “simplify its (company’s) dermatology ...

Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on ...

Hims & Hers Health ( NYSE: HIMS) shut down Apostrophe on Friday, the skincare business it acquired in 2019 for $190M. A ...

Hims and Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public ...

Hims & Hers Health stock opened at $49.10 on Friday. The business’s 50-day simple moving average is $35.05 and its two-hundred day simple moving average is $25.70. The company has a market cap ...

Hims & Hers Health shares swooned after the Food & Drug Administration said the active ingredient in Ozempic and Wegovy is no longer in short supply. The company makes compounded versions of ...

The acquisition will strengthen the long-term durability of the company’s domestic supply chain, helping to ensure Americans can consistently access personalized medications Hims & ...

Hims & Hers Health shares tumbled after a leading competitor said a shortage of its weight-loss treatments has been resolved, raising questions about the company's prospects in the space. Shares ...

Hims & Hers Health, Inc. (NYSE:HIMS) announced the acquisition of a California-based peptide facility to enhance its domestic supply chain and meet rising demand for personalized medications.